| Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review TL Ng, MM Tu, MFK Ibrahim, B Basulaiman, SF McGee, A Srikanthan, ... Supportive Care in Cancer 29, 925-943, 2021 | 47 | 2021 |
| A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer M Clemons, C Stober, A Kehoe, D Bedard, F MacDonald, MC Brunet, ... Supportive Care in Cancer 28, 4891-4899, 2020 | 24 | 2020 |
| Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT) B Basulaiman, AA Awan, D Fergusson, L Vandermeer, A Arnaout, J Hilton, ... Breast cancer research and treatment 177, 93-101, 2019 | 22 | 2019 |
| The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials FGT Fazzari, F Rose, M Pauls, E Guay, MFK Ibrahim, B Basulaiman, M Tu, ... Critical Reviews in Oncology/Hematology 169, 103540, 2022 | 12 | 2022 |
| A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia M Clemons, D Fergusson, AA Joy, K Thavorn, J Meza-Junco, JP Hiller, ... The Breast 58, 42-49, 2021 | 7 | 2021 |
| Mortality and morbidity of curative and palliative anticancer treatments during the COVID-19 pandemic: a multicenter population-based retrospective study E Tashkandi, A Al-Abdulwahab, B Basulaiman, A Alsharm, M Al-Hajeili, ... Molecular and Clinical Oncology 14 (4), 82, 2021 | 7 | 2021 |
| A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy A Robinson, C Stober, D Fergusson, A Kehoe, D Bedard, F MacDonald, ... Breast Cancer Research and Treatment 178, 337-345, 2019 | 7 | 2019 |
| A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in … M Clemons, D Simos, M Sienkiewicz, T Ng, L Zibdawi, B Basulaiman, ... Supportive Care in Cancer 29, 5787-5795, 2021 | 5 | 2021 |
| Fibroblast growth factor receptor 3 mutation as a prognostic indicator in patients with urothelial carcinoma: a systematic review and meta-analysis S Khalid, BM Basulaiman, J Emack, CM Booth, I Duran, AG Robinson, ... European Urology Open Science 21, 61-68, 2020 | 4 | 2020 |
| Observational study and literature review of the use of camel urine for treatment of cancer patients A Al Zahrani, A Alfakeeh, W Alghareeb, H Bakhribah, B Basulaiman, ... East Mediterr Health J 29 (8), 2023 | 3 | 2023 |
| Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial A Awan, B Basulaiman, C Stober, M Clemons, D Fergusson, J Hilton, ... Health Science Reports 4 (4), e443, 2021 | 3 | 2021 |
| P3. 01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience K Virik, B Basulaiman, A Robinson, W Hopman Journal of Thoracic Oncology 13 (10), S868, 2018 | 3 | 2018 |
| Thirty-day mortality after curative and palliative anti-cancer treatment: data interpretation and lessons for clinical implementation E Tashkandi, B Basulaiman, W Alghareeb, F Hamadi, A Alghamdi, ... Cancer Management and Research, 12301-12308, 2020 | 2 | 2020 |
| Use of camel urine is of no benefit to cancer patients: observational study and literature review A Al Zahrani, A Alfakeeh, W Alghareeb, H Bakhribah, B Basulaiman, ... Eastern Mediterranean Health Journal 29 (8), 657-663, 2023 | 1 | 2023 |
| Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review. TL Ng, MM Tu, MFK Ibrahim, BM Basulaiman, S McGee, A Srikanthan, ... Journal of Clinical Oncology 38 (15_suppl), e24083-e24083, 2020 | 1 | 2020 |
| A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of taxotere/cyclophosphamide-induced febrile neutropenia in patients … MJ Clemons, D Fergusson, AA Joy, J Meza-Junco, JA Price Hiller, ... Journal of Clinical Oncology 38 (15_suppl), 7001-7001, 2020 | 1 | 2020 |
| A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer AA Awan, B Basulaiman, A Robinson, C Stober, D Fergusson, AA Joy, ... Annals of Oncology 30, iii66-iii67, 2019 | 1 | 2019 |
| Conflict of interest:“Be rigorous in judging ourselves and gracious in judging others” B Basulaiman, A Awan, JF Hilton, M Clemons Current Oncology 25 (6), 355-357, 2018 | 1 | 2018 |
| A cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic … B Basulaiman, AA Awan, J Hilton, D Fergusson, C Stober, L Vandermeer, ... Annals of Oncology 30, iii68, 2019 | | 2019 |
| FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis. S Khalid, BM Basulaiman, J Emack, CM Booth, D Hernandez-Barajas, ... Journal of Clinical Oncology 37 (7_suppl), 411-411, 2019 | | 2019 |
